Covis Pharma B.V., a Holland-based privately held specialty pharmaceutical company, announced Wednesday a deal in which its for its Alvesco Inhalation Aerosol asthma treatment will be exclusively ...
ZUG, Switzerland--(BUSINESS WIRE)--Covis Pharma B.V. (“Covis Pharma”), a global specialty pharmaceutical company, is pleased to announce an agreement with Walgreens, one of the largest drugstore ...
ZUG, Switzerland, April 15, 2021 (GLOBE NEWSWIRE) -- Covis Pharma Group (the “Company”), a global specialty pharmaceutical company that markets therapeutic solutions for patients with life-threatening ...
Alvesco approved for asthma Sepracor has launched Alvesco (ciclesonide) inhalation aerosol for the prophylactic and maintenance treatment of asthma in patients ≥12 years of age. Sepracor has launched ...
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has entered into a definitive agreement to divest the U.S. market rights to Sunovion’s ciclesonide ...
U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) filing to study the use of Alvesco in COVID-19 Study will evaluate the Safety and Efficacy of Alvesco ...
The study will enroll 400 patients with symptomatic coronavirus disease 201. A phase 3 study evaluating the efficacy and safety of ciclesonide inhalation aerosol (Alvesco) in non-hospitalized patients ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Nonhospitalized patients with COVID-19 who received the ...
COVIS PHARMA GROUP Announces Top-line Safety and Efficacy Data from a Phase 3 Placebo-Controlled COVID-19 Study Using Inhaled Corticosteroid (ciclesonide) ZUG, Switzerland, April 15, 2021 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results